Molecular Templates, Inc. (MTEM): Price and Financial Metrics
Molecular Templates, Inc. (MTEM)
Today's Latest Price: $16.09 USD
Updated Feb 28 12:00am
Add MTEM to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 215 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
MTEM Stock Summary
- MTEM's price/sales ratio is 24.51; that's higher than the P/S ratio of 94.86% of US stocks.
- With a year-over-year growth in debt of 330.24%, Molecular Templates Inc's debt growth rate surpasses 94.14% of about US stocks.
- As for revenue growth, note that MTEM's revenue has grown 120.33% over the past 12 months; that beats the revenue growth of 95.2% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to Molecular Templates Inc, a group of peers worth examining would be PGNX, DNN, OMEX, VERU, and PTCT.
- Visit MTEM's SEC page to see the company's official filings. To visit the company's web site, go to www.mtem.com.
MTEM Stock Price Chart More Charts
MTEM Price/Volume Stats
| Current price | $16.09 | 52-week high | $18.38 |
| Prev. close | $15.66 | 52-week low | $4.51 |
| Day low | $14.86 | Volume | 330,700 |
| Day high | $16.20 | Avg. volume | 317,245 |
| 50-day MA | $14.48 | Dividend yield | N/A |
| 200-day MA | $9.27 | Market Cap | 594.83M |
Molecular Templates, Inc. (MTEM) Company Bio
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies for the treatment of cancer and other serious diseases. It develops MT-3724, a lead drug candidate that is in a Phase 1 clinical trial in heavily pre-treated non-Hodgkin's lymphoma patients; MT-4019, a preclinical drug candidate targeting CD38; and evofosfamide, an investigational hypoxia-activated prodrug of a bis-alkylating agent that is preferentially activated under severe hypoxic tumor conditions, a feature of many solid tumors. The company is based in Austin, Texas.
Top Stories View All
How Low Will Stocks Go?
Best & Worst Performing Stock Industries for February 28, 2020
Best & Worst Performing Small Cap Stocks for February 28, 2020
Best & Worst Performing Mid Cap Stocks for February 28, 2020
Best & Worst Performing Large Cap Stocks for February 28, 2020
View All Top Stories
Loading social stream, please wait...